215540581BENTRAL FAX CENTER HOWSON AND HOWSON

		TE	B 1 U 2006	0 Dala-1 1	PTO/SB/21 (09-04) Approved for use through 07/31/2008. OMB 0651-0031	
TRANSMITTAL FORM (10 be used for all correspondence after initial of Total Number of Pages In This Submission 1 Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/		e after initial filing) misaion 11 ENC pon(s) quest tement Rema	Application Number Filing Date First Named Inventor Art Unit Examiner Name Altorney Docket Number CLOSURES (Check : Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocat Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on C	Collection of in 10/701.33 November D. Cines 1633 S. Kaushar UPN-029 all that apply the apply that apply the apply that apply the apply that apply that apply the apply that apply that apply the apply	of 4, 2003	
Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		arts or 1.53	TURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name HOWSON AND HOWSON Signature **Thru E. Bek						
Printed name Mary E. Bak				31,215		
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Typed or printed name Robert J. Duminiat Date Feb. 10, 2006						

This collection of Information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED **CENTRAL FAX CENTER**

FEB 1 0 2006

UPN-O2906AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/701,331

Confirmation No.: 5594

Applicant

: D. Cines, et al.

Filed

: November 4, 2003

TC/A.U.

: 1633

Examiner

: S. Kaushal

Customer No.

: 00270

Title

: DELIVERY VEHICLE FOR RECOMBINANT PROTEINS

Mail Stop Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF TRANSMISSION OR MAILING UNDER 37 C.F.R. 1.8

I certify that this paper is being facsimile transmitted, or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, the United States Patent and Trademark Office, on the

date shown below.

Printed Name

Dated:_

RESPONSE UNDER 35 U.S.C. §121 AND AMENDMENT

Sir:

This paper is in timely response to the Office Action dated January 10, 2006.

Please enter the following election and claim amendments.

Election of Species begins on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks/Arguments begin on page 9 of this paper.

U.S. Patent Application No. 10/701,331 February 10, 2006 Response to Office Action dated January 10, 2006 Page 2 of 10

ELECTION OF CLAIMS

Applicants hereby elect, without traverse, the claims of Group I, i.e., Claims 9-10, 22 and 33-35, drawn to a recombinant nucleic acid comprising a platelet-specific promoter, a platelet transformed, transduced, infected or transfected thereby, and its therapeutic use. Applicants understand that the election of Group I includes, in part, generic or "linking" claims 1-8, 19-21, and 23-32.

Applicants hereby elect, with traverse, the following species:

megakaryotic/erythrocyte progenitor cells in claim 3;
megakaryocytes in claim 4;
neutrophils in claim 5;
dendritic cells in claim 7;
platelet factor 4 promoter in claim 10;
DEFA1 human neutrophil alpha defensin promoter in claim 12;
human eotaxin gene promoter in claim 16;
megakaryocytes in claim 21; and
u-PA in claim 34.